Fig. 4: MD39 constructs containing alternate linkers conjugated to pSer elicit strong humoral immune responses.
From: Optimization of an alum-anchored clinical HIV vaccine candidate
a BALB/c mice (n = 5 animals/group) were immunized with 10 µg Ser4- or pSer4-conjugated MD39 constructs and 100 µg alum and boosted with 5 µg Ser4- or pSer4-conjugated MD39 constructs and 50 µg alum with 5 µg SMNP at 6 weeks. Serum IgG responses were assessed longitudinally by ELISA. Arrows indicate immunizations. b Individual responses plotted for day 28. c Individual responses plotted for day 42. d Individual responses plotted for day 56. Values plotted are geometric means ± geometric standard deviation. Statistical significance was determined by two-way ANOVA followed by Tukey’s multiple comparison test. e Mice (n = 5 animals/group) were immunized with 5 µg pSer4- or Ser4-conjugated MD39_nohis8 construct and 50 µg alum with 5 µg SMNP, and germinal center (GC) B cell responses were assessed in the draining inguinal lymph nodes at day 14 and 21 post-immunization. f Shown are representative flow cytometry gating plots of MD39-specific GC B cell analysis, plotted in (g). Statistical significance was determined by two-way ANOVA followed by Tukey’s multiple comparison test. Values plotted are means ± standard deviation. ns p > 0.05, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
